Interest in “psychedelic therapies,” using substances such as ketamine, 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin to treat psychiatric conditions, has grown steadily in recent years. Although pharmacologically distinct and functioning via differential mechanisms, these drugs are broadly classified as hallucinogenic, meaning they are thought to produce hallucinations. However,...